Ginkgo Bioworks
Update in progressDNA (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ginkgo Bioworks and its subsidiaries operate a platform for cell engineering in the United States, with two segments: Cell Engineering and Biosecurity. It provides R&D solutions and tools for functional genomics, developability of antibodies and small molecules, AI models, and reconfigurable automation for engineered organisms and products. Canopy offers biomonitoring and bioinformatics, while Horizon covers digital surveillance and biothreat monitoring. Founded 2008, based in Boston.
Company score
- Sentiment
- 0.79
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.55
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.50
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.37
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.58
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationUnited States
- CEODr. Jason Kelly Ph.D.
- Founded2008
- Employees485
- Websitewww.ginkgo.bio
Identifiers
- ISINUS37611X2099
- FIGIBBG00YPS1KY3
- CUSIP37611X100
- CIK0001830214